Exact Sciences Corporation
EXASNASDAQHealthcare
$104.91
+$0.00(+0.00%)
Market Cap$20.0B
P/E Ratio—
52W High$104.98
52W Low$38.81
Exact Sciences Corporation (EXAS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EXAS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.25B | $2.76B | $2.50B | $2.08B | $1.77B |
| Cost of Revenue | $0.98B | $0.84B | $0.74B | $0.66B | $0.46B |
| Gross Profit | $2.26B | $1.92B | $1.76B | $1.42B | $1.31B |
| Gross Margin %(computed) | 69.69% | 69.55% | 70.49% | 68.27% | 74.04% |
| Operating Expenses | |||||
| R&D Expenses | $0.52B | $0.43B | $0.43B | $0.39B | $0.39B |
| G&A Expenses | $0.89B | $1.42B | $1.39B | $0.66B | $0.80B |
| Total Operating Expenses | $2.36B | $2.97B | $1.98B | $2.02B | $2.16B |
| Operating Income | ($0.10B) | ($1.05B) | ($0.22B) | ($0.59B) | ($0.86B) |
| Operating Margin %(computed) | -3.05% | -38.01% | -8.60% | -28.48% | -48.42% |
| Interest Income | $0.04B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.03B | $0.02B | $0.01B | $0.01B |
| Income Before Tax | ($0.20B) | ($1.04B) | ($0.20B) | ($0.63B) | ($0.84B) |
| Income Tax Expense | $0.00B | ($0.01B) | $0.00B | ($0.01B) | ($0.25B) |
| Net Income | ($0.21B) | ($1.03B) | ($0.20B) | ($0.62B) | ($0.60B) |
| Net Margin %(computed) | -6.40% | -37.29% | -8.17% | -29.91% | -33.71% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.10 | $-5.59 | $-1.13 | $-3.54 | $-3.48 |
| Wtd Avg Shares | 0.19B | 0.18B | 0.18B | 0.18B | 0.17B |
| EBITDA | $0.12B | ($0.79B) | $0.03B | ($0.42B) | ($0.65B) |
| EBITDA Margin %(computed) | 3.77% | -28.61% | 1.17% | -20.20% | -36.74% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Exact Sciences Corporation data
About Exact Sciences Corporation (EXAS) Income Statement
Exact Sciences Corporation (EXAS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EXAS reported revenue of $3.25B, gross profit of $2.26B (gross margin 69.69%), and net income of ($0.21B) — a net profit margin of -6.40%.
Frequently asked questions
EXAS · 4 questionsExact Sciences Corporation (EXAS) reported revenue of $3.25B for 2025, up 17.7% year-over-year.
EXAS revenueEXAS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08